Altimmune(US:ALT) Prnewswire·2025-09-24 13:40Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after disappointing trial results for Pemvidutide, with a reminder of the upcoming deadline for investors to seek lead plaintiff status in a federal securities class action [2][3][4]. Group 1: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction, despite prior inflated expectations [3]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [4]. Group 2: Legal Actions - Investors who suffered losses exceeding $75,000 in Altimmune between August 10, 2023, and June 25, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The firm is reminding investors of the October 6, 2025, deadline to seek the role of lead plaintiff in the class action lawsuit against Altimmune [2][5].